STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Cortagen

Also known as

AEDP · Ala-Glu-Asp-Pro · H-Ala-Glu-Asp-Pro-OH · AEDP peptide · AEDP tetrapeptide · cortex bioregulator · Cortagen peptide · cortex tetrapeptide · cerebral-cortex tetrapeptide · Khavinson Cortagen · Cortexin synthetic analog (AEDP) · SCHEMBL5491754 (database synonym, vendor listings)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Niche talk Mixed SubQ / IM / Oral / IN Longevity & bioregulators

Mixed — cortex/CNS- and nerve-framed synthetic AEDP; community short courses are systemic, not local injury-site dosing or Cortexin extract.

What people say Cortagen is synthetic Ala-Glu-Asp-Pro (AEDP), a defined tetrapeptide derived from the Cortexin research lineage. It is not the multi-peptide Cortexin animal-brain extract. Doses people talk about
Common injectable chart~0.5–2 mg once daily SubQ or IM

Most repeated short-course vendor/community band; not a labeled human regimen.

Broader secondary range~0.1–5 mg/day

Occasional writeups with likely extract-era or marketing bleed; not one trial ladder.

Lower community range~200–400 mcg/day

Less standardized forum/protocol range than the 0.5–2 mg charts.

Intranasal discussion~0.1–1 mg intranasal

Minority secondary-chart range with uncertain bioavailability.

Rat nerve study10 µg/kg IM daily for 10 days

Post-transection/suture Wistar-rat experiment; not a human conversion or recipe.

Mouse behavior study0.01–0.10 mg/kg IP

Acute or multi-day locomotor/anxiety assays; not human SubQ exposure.

Synthetic AEDP, Cortexin extract, oral products and injectable research material are not exposure-equivalent; animal mg/kg values remain animal study context. Oral catalog products: Brand-variable capsule count and peptide mass. Oral cytogen-style products appear in short-course catalogs; oral milligrams are not automatically bioequivalent to injectable AEDP.

Half-life & effect duration

Half-life in the body
  • Half-lifeNo settled estimate
Felt duration people report
  • One repeated-use accountSleeping through the night and half the day by about day 5
  • Another stacked-use accountImprovement over 2 days while recovering from illness
  • Post-course community claimEffects may persist about 2–4 weeks
Timing context & sources
How it may feel The community record is sparse. One poster using 4 mg/day for about five days reported sleeping through the night and half the day; another dramatic positive report combined acute illness recovery, Semax, nootropics, Cortagen and 30 mg immediate-release Adderall.
Cycles people discuss Historical discussion clusters around 10–20-day courses, sometimes 10–14 days for nerve-interest logs, with multi-month gaps. These calendars come from bioregulator culture and an animal-course precedent, not human dose-finding or PK. Timing Retained reports favor morning use and describe some higher evening doses as activating or sleep-disruptive. Oral routines and food rules vary by product; minority nasal use appears in morning CNS stacks. These are reported preferences, not validated timing rules. Stacks Pinealon and Epitalon appear in Khavinson rotations, while Semax or Selank appear as acute nootropic comparisons. These multi-agent patterns make single-compound attribution especially weak. Watch for Extract ≠ synthetic caution: Safety and clinical reputation of Cortexin extract do not automatically apply to synthetic research-chem AEDP from an unregulated vendor.
Related
CortexinPinealonEpitalonSemax

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

A product-specific human elimination half-life for synthetic AEDP Cortagen was not established in the reviewed material.

The directly inspected indexed study used 10 µg/kg IM daily for 10 days in rats after sciatic-nerve transection and measured regeneration and conduction, not plasma AEDP kinetics.

Bounded review of the indexed animal record and accessible community material; it does not prove global absence, and generic unprotected-peptide clearance assumptions are not Cortagen measurements.

Felt duration people report

The inspected Cortagen accounts do not establish a repeatable onset or per-dose felt-duration window.

One author using 4 mg/day for about five days reported sleeping all night and half the day but supplied no later outcome. Another reported a dramatic two-day improvement while recovering from acute illness and simultaneously using Semax, nootropics, Cortagen and 30 mg immediate-release Adderall.

Two sparse, unverified and highly confounded reports; one lacks route and follow-up, and the other cannot isolate Cortagen from recovery or multiple active agents.

What people say 15

  • Focus / fog (community): Multi-week course logs sometimes report clearer focus, quieter mental noise, or better mental stamina—subtle and easily confounded by sleep, stack mates, and expectation. forum
  • Stress composure (anecdote): Minority logs describe feeling more composed under work or training stress rather than wired or sedated. anecdote
  • Not a same-day “feel-it” nootropic: Community consensus frames Cortagen as a chronic substrate / course compound, not a 30-minute Semax-style hit. forum
  • Peripheral-nerve community use cases: Entrapment neuropathies (ulnar, brachial plexus, sciatic irritation), post-surgical nerve healing, and “diabetic-style neuropathy” interest are driven mainly by the rat sciatic data, not human RCTs. forum
  • Post-concussion / TBI-adjunct interest: Community and Eastern-European-adjacent writeups borrow Cortexin/Cerebrolysin clinical culture; synthetic AEDP itself lacks a controlled human concussion package. forum
  • Longevity rotation halo: Looksmaxx / longevity forums rotate Cortagen with Epitalon and Pinealon on a pulsed Khavinson calendar; single-agent credit is weak. forum
  • AAS / stim “cortical buffer” talk: Some physique-focused posts run Cortagen during heavy stimulant or AAS periods as an unproven neuroprotective adjunct—no interaction trials. anecdote
  • Stack confound: Often co-run with Pinealon, Epitalon, Semax/Selank, or BPC-157; isolating Cortagen’s contribution is hard. forum
  • Sciatic-nerve regeneration (rats): IM Cortagen 10 µg/kg daily for 10 days after sciatic transection/suture increased regenerating-fiber growth rate ~27% and conduction velocity ~40% vs control (Turchaninova et al., Bull Exp Biol Med 2000; PMID 11276314). animal
  • Delayed nerve recovery (rats): Follow-up work reports delayed/functional recovery effects after the same class of Cortagen nerve protocol (Kolosova et al., related PMID 12134478). animal
  • Cortex explants (in vitro): Organotypic brain-cortex explant work reported stimulated growth of tissue matching the parent cytomedin’s origin—tissue-specific explant signal, not a human cognition trial (PMID 11713572 lineage). lab
  • Gene-expression microarray (mice): Five consecutive days of Cortagen shifted expression of a defined transcript set in mouse heart (~110 genes cited in secondary summaries; up to multi-fold up/down in the Anisimov 2004 screen; PMID 15159690)—mechanistic, not a human endpoint. animal
  • Motor / arousal without big anxiety shift (mice): IP 0.01 / 0.03 / 0.10 mg/kg; 0.03 mg/kg enhanced locomotion acute and sub-chronic with few anxiety-axis effects on EPM, contrasting Cortexin’s mixed anxiolytic/anxiogenic pattern (Adriani et al.). animal
  • Ischemic neuroprotection (animal models): Secondary literature cites amelioration of neurological/metabolic disturbances under cerebral ischemia and potentiation of ischemic preconditioning (e.g., Zarubina & Shabanov 2016 writeups)—preclinical only. animal
  • What it is not proven for: No high-quality evidence it treats Alzheimer’s, cures TBI, regenerates human peripheral nerves on a clinical schedule, or extends lifespan. trial

Doses people talk about 16

  • No validated human dose: Synthetic Cortagen has no published clinical dose-finding study; circulating mg figures inherit Russian bioregulator “course” culture and animal-study course lengths more than human titration. forum
  • Common injectable research-chem band: ~0.5–2 mg once daily SubQ or IM across a short course is the band most often repeated on vendor/community dosing pages. forum
  • Low entry (community charts): ~500–1000 mcg (0.5–1 mg) once daily — described as entry-level / tolerability-first. forum
  • Mid band (most-cited community “working” range): ~1000–2000 mcg (1–2 mg) once daily. forum
  • High community tier: ~1.5–2 mg once daily; some educational pages warn evening dosing at the ~2 mg tier can feel over-stimulating and fragment sleep. forum
  • Broader secondary writeups: Occasional pages float adult ranges from ~0.1 mg up to ~5 mg/day depending on “neurological condition” language—often extract-era or marketing bleed; not a single trial ladder. forum
  • Body-weight–style community rule of thumb: Some blogs restate ~10 µg/kg as a “common guideline” borrowed from animal/nerve context; that is not an allometrically validated human conversion. forum
  • Lower mcg band (less standardized): Forum/protocol pages sometimes cite ~200–400 mcg/day (or fixed morning 200 mcg unit charts) — thinner consensus than the 0.5–2 mg band. forum
  • Intranasal (minority experimental talk): Secondary charts sometimes list ~0.1–1 mg intranasal as a CNS-targeting discussion option with uncertain bioavailability; far less standardized than SubQ. forum
  • Titration convention (community, not trial): Half-dose first week (~1 mg) then step to ~2 mg to reduce early-headache reports; no loading phase in the anabolic-peptide sense. forum
  • Oral capsules / cytogen-style products: Short oral courses appear in bioregulator catalogs (capsule count and labeled peptide mass vary by brand); oral mg is not automatically bioequivalent to SubQ research-vial mg. forum
  • Purity / label risk: Labeled mg may not equal delivered AEDP without third-party COA; underdosing and wrong-sequence research peptides are a known category problem. forum
  • Animal nerve protocol (not a human recipe): Rats 10 µg/kg IM daily × ~10 days post sciatic injury (PMID 11276314). animal
  • Framing: Research-chem vendor charts, forum self-reports, and clinic-marketing templates only — not medical advice, not validated human dose-finding, not FDA-labeled protocols. Ranges disagree; treat disagreement as a core fact. forum
  • Animal behavior protocol: Mice IP 0.01–0.10 mg/kg (mid ~0.03 mg/kg) acute or multi-day — locomotor/anxiety assays, not human SubQ charts. animal
  • Animal cognitive/neuroplasticity research tables (vendor-style): Secondary research-reference sheets list rodent bands such as ~0.1–1 mg/kg daily for 10–20 days, ~0.25–1 mg/kg for 14–30 days, or cyclic 10 on/10 off at ~0.5–2 mg/kg — laboratory ranges only. animal

How it may feel 8

  • Days 1–3: Little acute sensation for most; not framed as a same-day stimulant. Minority early “flatness,” mild headache, or injection-site awareness. forum
  • Days 4–10: First subtle clarity, stress-load composure, or “nothing yet” notes; community cognitive talk often clusters mid-course rather than day one. anecdote
  • Days 7–14 (nerve-interest logs): Peripheral-nerve experimenters sometimes track paresthesia, grip, or symptom maps across a 10–14 day block—still uncontrolled n=1. anecdote
  • Days 11–20 / end of short course: End of the dominant 10–20 day block; rarely a strong on/off “coming off” crash. Responders describe gradual settle more than a flip switch. forum
  • Weeks 2–4 (community window): First self-described cognitive or recovery impressions often land late in course or just after—gradual and easy to misattribute. forum
  • 2–4 weeks post-course (lore): Residual tissue/gene-program effect claims (clarity or nerve symptom drift) are common bioregulator lore; not measured in human PK/PD trials for AEDP. anecdote
  • No change after one course: Common and fully consistent with a sparse human evidence base; forums recheck product identity (Cortexin extract vs AEDP), COA/purity, sleep, co-stacks, and whether expectations were stimulant-shaped. forum
  • Animal durability note: Rat nerve endpoints were tracked out toward ~five months after a 10-day IM course—animal durability, not a human plateau chart. animal

Cycles people discuss 8

  • Dominant course length: ~10–20 consecutive days on is the most repeated research-chem / bioregulator pattern. forum
  • Extended community pulse: Some protocol pages stretch cognitive courses to ~20–28 days on, then long washout. forum
  • Nerve-recovery blocks: Community nerve-interest talk often cites ~10–14 days daily, echoing the 10-day rat IM course length. forum
  • Yearly rhythm: Often ~2–4 courses/year (some writeups say 2–3) with multi-month gaps; mirrors Russian bioregulator cadence more than continuous peptide culture. forum
  • Time off: Common community gaps are ~1–2 months, or ≥8 weeks after a 20–28 day block; continuous multi-month daily dosing is uncommon. forum
  • Pulse logic (lore): Gene/tissue narrative argues effects persist after plasma clearance, so cruising is framed as wasteful—lore, not human PK proof. forum
  • Injury-timed starts: Peripheral-nerve discussion sometimes starts the course soon after injury/surgery in animal-inspired n=1 designs—not a controlled clinical protocol. forum
  • Khavinson rotation cadence: Cortagen 20-day block → washout → Epitalon block → washout → Pinealon block (order varies); two full rotations/year appears in educational stack writeups. forum

Timing 8

  • Plasma half-life: No product-specific human plasma half-life for synthetic Cortagen was located in the reviewed sources. Generic short-peptide minutes-scale assumptions are not a measured AEDP value. forum
  • Why daily-course talk persists: Community course logic invokes repeated transcriptional or tissue signaling rather than steady plasma exposure, but no product-specific human PK or validated dosing-frequency link was located. forum
  • Downstream / residual claim: Community and secondary guides often say biological effects may persist ~2–4 weeks after the last dose of a course; animal nerve durability was tracked much longer—human residual effect is unmeasured. anecdote
  • Injection timing — morning default: Morning SubQ is the common preference because of mouse motor-stimulation data and user reports that higher evening doses can feel activating. forum
  • Evening caution at higher tier: Educational pages specifically flag ~2 mg evening use as potentially sleep-disruptive for some. forum
  • Oral timing: With daily routine; food-timing rules are not standardized across brands. forum
  • Intranasal timing (minority): Sometimes paired with morning Semax/Selank stacks when users run multi-route CNS stacks. forum
  • Not acute PRN: Unlike rescue nootropics, Cortagen is almost always discussed as a fixed daily course, not as-needed. forum

More on what it is 7

  • Why people search it: Cognition, stress composure, nerve-recovery, and longevity-stack talk—usually next to Pinealon, Epitalon, and (confusingly) Cortexin extract writeups. forum
  • What it is: Synthetic tetrapeptide Ala-Glu-Asp-Pro (one-letter AEDP; often written H-Ala-Glu-Asp-Pro-OH), a short Khavinson-family bioregulator developed from amino-acid analysis of the bovine cerebral-cortex extract Cortexin. Approximate MW ~430 g/mol is commonly listed on research-chem pages (vendor formulas occasionally disagree—check COA/sequence, not marketing synonyms). trial
  • Origin story: Directed synthesis by Vladimir Khavinson’s group as a simplified active-fraction analog of Cortexin; sold today as research-chemical lyophilized powder or as oral “cytogen”-style bioregulator products depending on brand. trial
  • Mechanism talk: Originator-line claim that short peptides enter cells/nucleus, interact with DNA/histones, and modulate tissue-specific gene expression (transcriptional “nudge” rather than surface-receptor rush); also BDNF/NGF and synaptic-scaffold narratives in secondary writeups. Human proof of that cascade for injected AEDP is sparse. trial
  • Evidence posture: Small, older Russian preclinical cluster (rat sciatic regeneration, cortex explants, mouse microarray/behavior, ischemia models). No large modern Western human RCTs of synthetic Cortagen; independent multi-center replication is effectively absent. animal
  • Extract ≠ synthetic: Cortexin is a multi-peptide tissue extract with a clinical-use history in some jurisdictions; Cortagen is the synthetic AEDP tetrapeptide. Extract human narratives do not automatically transfer to research-chem AEDP. trial
  • What it is not: Not Cortexin extract, not Pinealon (EDR), not Epitalon (AEDG), not Cerebrolysin, not a same-day stimulant nootropic like Semax, not FDA-approved for cognition or nerve repair. trial

Stacks 9

  • With Pinealon (EDR): Most common brain-bioregulator pair—same short course or adjacent blocks for cognition/longevity talk; multi-agent confound is high. forum
  • With Epitalon (AEDG): Sequential or overlapping longevity courses; Epitalon framed as pineal/telomere-axis, Cortagen as cortex/nerve—complementary lore, not a proven synergy trial. forum
  • Khavinson rotation: Cortagen → washout → Epitalon → washout → Pinealon (or similar order), ~2 rotations/year in educational stack pages. forum
  • Semax / Selank adjacency: Cortagen as multi-week “substrate,” Semax (~300 mcg IN in some charts) or Selank (~250–500 mcg IN) as same-day acute focus/calm—different timescales, still confounded. forum
  • BPC-157 ± TB-500 (recovery stack): Physique/nerve threads pair Cortagen’s axonal-growth narrative with BPC-157 (~250–500 mcg SubQ in common charts) soft-tissue/vascular repair for entrapment or post-surgical nerve talk. forum
  • Broader organ cytogens: Yearly rotations sometimes include Cartalax, Livagen, Cardiogen, or other tissue bioregulators alongside cortex-directed AEDP. forum
  • Cerebrolysin co-mention: Post-TBI community discussion sometimes names Cerebrolysin (complex peptide extract) next to cortex peptides—different product class; not interchangeable. forum
  • On-cycle AAS co-use talk: Framed as additive neurotrophic/antioxidant interest with no documented endocrine interaction panel specific to Cortagen. anecdote
  • Lifestyle confounders often co-credited: Sleep, stress load, cognitive training, and stimulant hygiene are routinely named alongside any perceived benefit. forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 16

  • Injection site: Mild redness, itch, tenderness, or swelling at SubQ sites is the most consistent community class effect; site rotation and smaller volumes are the usual mitigation talk. forum
  • Early flatness / muted energy: Brief low-energy window in the first few doses appears in sparse bioregulator logs. anecdote
  • Early-cycle headache: Mild headache is among the more common subjective notes, especially when starting at higher (~2 mg) tiers without a step-in week. forum
  • Nonspecific class effects: Occasional fatigue, mild nausea, or light-headedness appear in general injectable-peptide community discussion—not Cortagen-specific trial endpoints. forum
  • Sleep disruption risk (dose/timing): Evening administration at the upper community tier is flagged as potentially over-stimulating. forum
  • Supply-chain > molecule for many risks: Non-pharma production, sterility/endotoxin contamination, mislabeling, underdosing, and wrong sequence are documented research-chem category problems; COA shopping is community practice, not a guarantee. forum
  • Infection / technique risk: Any self-injection carries local infection, abscess, or sterile-technique failure risk independent of peptide identity. forum
  • Pause/eval red flags (community pattern): Fever/chills after injection, spreading redness/streaking/pus, persistent site reactions, or allergic-type reactions (rash, swelling, breathing difficulty) are treated as product/technique emergencies, not “expected peptide sides.” forum
  • Expectation gap: Animal nerve and gene papers are not proof of a reliable human cognitive therapy; non-response is common and informative. forum
  • Long-term unknown: No multi-year controlled human safety data on repeated synthetic Cortagen courses; if gene-expression modulation is real, long-horizon implications are unquantified. forum
  • Interactions: No systematic drug-interaction matrix in forum charts or modern labels; stack polypharmacy is common and confounds both benefit and harm attribution. forum
  • Special populations: Pregnancy, lactation, active malignancy, uncontrolled epilepsy, and serious psychiatric illness are generally treated as avoid/unknown zones in community caution lists—not because trials mapped risk, but because data is empty. forum
  • Evidence gap first: Originator literature often describes bioregulator peptides as practically non-toxic / near-zero side effects in their preclinical settings—that is single-lineage, largely uncontrolled observation, not independent Western human pharmacovigilance. Data absence ≠ proven safety. trial
  • Mouse motor stimulation reminder: Preclinical locomotor activation without strong anxiety shift supports the “clean activation / AM only” preference—still not a human side-effect table. animal
  • Extract ≠ synthetic caution: Safety and clinical reputation of Cortexin extract do not automatically apply to synthetic research-chem AEDP from an unregulated vendor. trial
  • Regulatory framing: Research-only / not for human consumption labeling on research-chem vials; not FDA-approved for cognition, stroke, TBI, or nerve repair. forum

Updated: 2026-08-12

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →